Congress quietly expands no-bid contracts for drug makers in biodefense bill

What it does

This bill expands the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services to award follow-on production contracts without competitive bidding to companies that win initial prototype development contracts, procure supplies for experimental purposes using non-competitive procedures, and acquire innovative commercial products through a streamlined process. Companies that develop prototypes for BARDA can now be awarded production contracts directly, bypassing normal competitive procurement rules, provided the initial prototype selection used competition.

Why we flagged it

The bill's core function is to expand BARDA's contracting flexibility, but the operative mechanism—allowing non-competitive follow-on production contracts—represents a significant departure from standard federal procurement rules. The title (FLASH Act) obscures this procurement deregulation behind emergency-response framing.

What the text implies

• Follow-on production contracts can be awarded without competitive bidding if the initial prototype selection was competitive, creating a two-stage process where only the first stage faces price competition. Subsequent production orders—potentially worth far more than prototype development—escape competitive pressure.
• The $100M threshold for written efficacy determination is high; contracts just under this amount face no such review, and even those above it require only a written determination, not external approval or competitive justification.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers (prototype developers eligible for follow-on production contracts); medical device companies; contract research organizations